Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NCF1 | P14598 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 6/20 | 0.35 |
| ▸ | CA12 | O43570 | 4/20 | 0.35 |
| ▸ | CA1 | P00915 | 4/20 | 0.35 |
| ▸ | CA4 | P22748 | 4/20 | 0.35 |
| ▸ | CA9 | Q16790 | 4/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | GLP1R | P43220 | 8/20 | 0.32 |
| ▸ | CTH | P32929 | 1/20 | 0.31 |
| ▸ | CBS | P35520 | 1/20 | 0.31 |
| ▸ | THPO | P40225 | 1/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4283146 | 0.91 | MEN1 (0.41) | MEN1KMT2ANCF1CA2CA12 | |
| SCHEMBL12029017 | 0.91 | MEN1 (0.44) | MEN1KMT2ANCF1CA2CA12 | |
| SCHEMBL7951389 | 0.87 | MEN1 (0.41) | MEN1KMT2ANCF1CA2CA12 | |
| SCHEMBL15473930 | 0.86 | MEN1 (0.42) | MEN1KMT2ANCF1CA2CA12 | |
| SCHEMBL25241161 | 0.84 | TSHR (0.43) | MEN1KMT2ANCF1CA2CA12 | |
| SCHEMBL15494035 | 0.84 | MEN1 (0.41) | MEN1KMT2ANCF1CA2CA12 | |
| SCHEMBL4283153 | 0.84 | MEN1 (0.37) | MEN1KMT2ANCF1CA2CA12 | |
| SCHEMBL17903280 | 0.84 | MEN1 (0.41) | MEN1KMT2ANCF1CA2CA12 | |
| SCHEMBL15765871 | 0.84 | MEN1 (0.37) | MEN1KMT2ANCF1CA2CA12 | |
| SCHEMBL270173 | 0.84 | MEN1 (0.39) | MEN1KMT2ANCF1CA2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9683006-B2 | Method of purifying/concentrating sugar chains with a sugar chain-trapping molecule and method of analyzing sugar chain structure | SUMITOMO BAKELITE CO., LTD. (JP) | 2017-06-20 | — | — | US | disclosed |
| US-9139607-B2 | Method of purifying/concentrating sugar chain with sugar chain-trapping molecule and method of analyzing sugar chain structure | SUMITOMO BAKELITE CO., LTD. (JP) | 2015-09-22 | — | — | US | disclosed |
| US-20150175652-A1 | METHOD OF PURIFYING/CONCENTRATING SUGAR CHAINS WITH A SUGAR CHAIN-TRAPPING MOLECULE AND METHOD OF ANALYZING SUGAR CHAIN STRUCTURE | SUMITOMO BAKELITE CO (JP) | 2015-06-25 | — | — | US | disclosed |
| EP-1577293-B1 | METHOD OF PURIFYING/CONCENTRATING SUGAR CHAIN WITH SUGAR CHAIN-TRAPPING MOLECULE AND METHOD OF ANALYZING SUGAR CHAIN STRUCTURE | SHIONOGI & CO (JP) | 2014-06-18 | — | — | EP | disclosed |
| US-20060188996-A1 | Method of purifying/concentrating sugar chain with sugar chain-trapping molecule and mehtod of analyzing sugar chain structure | SHIONOGI CO., LTD. (JP) | 2006-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150175652-A1 | METHOD OF PURIFYING/CONCENTRATING SUGAR CHAINS WITH A SUGAR CHAIN-TRAPPING MOLECULE AND METHOD OF ANALYZING SUGAR CHAIN STRUCTURE | SLC2A2, SLC2A1, SLC2A4 | MEN1 3475/4885KMT2A 4114/4885NCF1 2173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.